<table id="ID115" width="99%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 13. Established and Other Potentially Significant Drug Interactions </caption>
<col width="31%"></col>
<col width="32%"></col>
<col width="36%"></col>
<tfoot>
<tr>
<td align="left" colspan="3">
<paragraph>↓= Decreased (induces lamotrigine glucuronidation).<br/>
</paragraph>
<paragraph>↑= Increased (inhibits lamotrigine glucuronidation). <br/>
</paragraph>
<paragraph>?= Conflicting data.<br/>
</paragraph>
</td>
</tr>
</tfoot>
<tbody>
<tr>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="bottom">Concomitant Drug<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="bottom">Effect on Concentration of <br/>Lamotrigine or Concomitant Drug<br/>
</td>
<td align="center" stylecode=" Lrule Rrule Botrule Toprule" valign="bottom">Clinical Comment<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Estrogen-containing oral <br/>contraceptive preparations containing <br/>30 mcg ethinylestradiol and <br/>150 mcg levonorgestrel <br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ lamotrigine <br/>
<br/>
<br/>
<br/>↓ levonorgestrel <br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Decreased lamotrigine levels approximately 50%. <br/>
<br/>
<br/>
<br/>Decrease in levonorgestrel component by 19%. <br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Carbamazepine (CBZ) and CBZ epoxide <br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ lamotrigine <br/>
<br/>
<br/>
<br/>? CBZ epoxide <br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Addition of carbamazepine decreases lamotrigine <br/>concentration approximately 40%. <br/>
<br/>
<br/>May increase CBZ epoxide levels <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Phenobarbital/Primidone <br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ lamotrigine <br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Decreased lamotrigine concentration approximately 40%. <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Phenytoin (PHT) <br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ lamotrigine <br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Decreased lamotrigine concentration approximately 40%. <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Rifampin <br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↓ lamotrigine <br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Decreased lamotrigine AUC approximately 40%. <br/>
</td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Valproate <br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">↑ lamotrigine  <br/>
<br/>
<br/>? valproate <br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Increased lamotrigine concentrations slightly<br/>more than 2-fold. <br/>
<br/>Decreased valproate concentrations an average of<br/>25% over a 3-week period then stabilized in healthy<br/>volunteers; no change in controlled clinical trials in<br/>epilepsy patients. <br/>
</td>
</tr>
</tbody>
</table>